Independent study proves Allen Carr’s Easyway is the most effective quit-smoking method – Ireland
The leading quit smoking treatment, Allen Carr’s Easyway to Quit Smoking Seminars, which is completely drug free, has today received a major boost as a fully independent Randomised Control Trial (RCT) on behalf of the Irish Government has found that it is twice as effective as the techniques currently offered by the Irish Health Service (which include nicotine patches and gum).
National 12-month Clinical Trial finds it twice as effective as other smoking cessation methods available on Health Service.
The leading quit smoking treatment, Allen Carr’s Easyway to Quit Smoking Seminars, which is completely drug free, has today received a major boost as a fully independent Randomised Control Trial (RCT) on behalf of the Irish Government has found that it is twice as effective as the techniques currently offered by the Irish Health Service (which include nicotine patches and gum). The trial results were reported in the BMJ’s Tobacco Control Journal on 26 October 2018.
John Dicey, Global CEO of Allen Carr’s Easyway comments:
“This is a landmark day as, for the first time, it presents the results of the program’s performance in a robust clinical trial. There is no doubt that being a cognitive (spoken) method doesn’t make it particularly suitable for this kind of clinical trial, but even in these circumstances, we’re delighted that the method was found to be twice as effective as the current treatments available in Ireland. We are also expecting the findings of a London-based RCT to be published soon, which should confirm that Allen Carr’s Easyway method is better than, or at least as good as, the current gold standard One-to-One NHS Quit Smoking Service. This should pave the way for this drug-free, quick & easy method to be made available via the Irish Health Service and the NHS.”
The results of the trial show that Allen Carr’s Easyway quit rates were ALWAYS superior to Quit.ie, consistently achieving higher quit rates at 1, 3, 6 and 12 months.
Brenda Sweeney, Allen Carr’s Easyway Ireland’s Managing Director, said:
“These results should give the Irish Health Service Executive (HSE) the confidence to make Allen Carr’s Easyway to Quit Smoking Seminar program available as an exciting alternative to nicotine patches, nicotine gum, and other treatments in Ireland. Working together, we can now provide a realistic and more cost-effective opportunity to free Ireland of smoking—after all, that was the reason that the Irish Government’s Health Minister pushed so hard for the study to be done.”
Professor Sofia Ravara, Chair of Group for the influential European Respiratory Society Tobacco Control Committee welcomes the study with enthusiasm, saying:
“I found the study very useful and hope we don’t have to wait another 30 years for Allen Carr to be a validated smoking cessation method.”
It is believed that this is the first time that such a therapy has been subjected to the rigors of a full RCT. The Allen Carr‘s Easyway to Quit Smoking Seminar Program does not rely on any nicotine, nicotine substances, patches, or other pharmaceuticals. It challenges the reasons why people smoke, and most people report that they not only quit smoking, but actually lose the desire to smoke.
John Dicey continues:
“Adding our program to their menu of services would not only save hundreds and thousands more lives but also save the HSE and the NHS millions of pounds a year. While many health bodies continue to promote the use of NRT, Champix, Zyban and e-cigarettes, it’s surely essential that they also provide an alternative that is 100% safe, drug-free, and proven—especially one that would excite and encourage smokers to seek assistance to quit. Allen Carr’s Easyway organisation is even prepared to offer its famous money-back guarantee to the HSE and the NHS. With nicotine patches and gum alone currently costing the NHS in excess of £27 million per year and smoking estimated to cost the health service in excess of £2.7 billion a year, we are confident that introducing our method will make a major impact to success rates and cost savings for the health service.”
